Guillain-Barré syndrome is a rare disease in which the immune system attacks the peripheral nerves. Those affected suffer from muscle weakness and paralysis. A research team led by ETH Zurich has now elucidated the mechanism of this autoimmune reaction. Patients with Guillain-Barré syndrome (GBS) suffer from a rare and diverse disorder of the peripheral nervous
New research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, shows that patients with refractory juvenile systemic sclerosis improved significantly on nearly all measures for two years following autologous stem cell transplant (Abstract #L06). Juvenile-onset systemic sclerosis (jSSc), also called scleroderma, is a disfiguring autoimmune disorder marked by hardening of the skin
Mutations in the RIPK1 gene responsible for CRIA syndrome. Over the last 20 years, three families have been unsuspectingly linked by an unknown illness. Researchers at the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health, and other organizations have now identified the cause of the illness, a new disease called
– Approval supported by data from the pivotal Phase 3 SELECT rheumatoid arthritis program evaluating nearly 4,400 patients– In five pivotal Phase 3 studies, RINVOQ™(upadacitinib) met all primary and ranked secondary endpoints across a variety of adult patient populations with moderate to severe active rheumatoid arthritis– RINVOQ, given alone or with csDMARDs, demonstrated improved rates
Annexon Biosciences, a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ANX005 for the treatment of Guillain-Barré Syndrome (GBS), a rare, acute, antibody-mediated autoimmune disease impacting
We often take our immune and nervous systems for granted. We assume that our immune system will protect us from diseases and when pathogens invade our body. Likewise, we assume that our nervous system will take information from the environment, relay it to our brain and then allow our brain to move muscles. But what
The designation is based on the results of the Phase II NOBILITY study that showed Gazyva, in combination with standard of care, helped more people achieve a complete renal response than standard of care alone Genentech today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Gazyva® (obinutuzumab) for
Allergic diseases have become a global health problem and the most prevalent allergic disorders include allergic asthma, allergic skin diseases, allergic rhinitis, and allergic conjunctivitis. In the therapy of allergic diseases, corticosteroids, antihistamines, antileukotrienes and β2 adrenergic receptor agonists temporarily inhibit inflammation mediators and immune cells. However, long-term treatment causes various adverse effects. Drug resistance and intolerance
The FDA approved upadacitinib (Rinvoq, AbbVie), a 15-mg, once-daily oral Janus kinase inhibitor, for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate. The approval is supported by data from the SELECT program, one of the largest registrational phase 3 clinical programs
